Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Arcadia Biosciences, Inc. issued to purchase up to 1,617,190 shares of Common Stock of warrant to certain investors (Participating Holders) for exercise of outstanding preferred investment options at reduced exercise price of $2.575 per share, aggregate gross proceeds of approximately $2.1 million.
- Security
- warrant
- Shares
- to purchase up to 1,617,190 shares of Common Stock
- Purchaser
- certain investors (Participating Holders)
- Consideration
- exercise of outstanding preferred investment options at reduced exercise price of $2.575 per share, aggregate gross proceeds of approximately $2.1 million
Exact text from the filing
the Participating Holders agreed to exercise for cash the Existing Options at a reduced exercise price of $2.575 per share, in consideration for the Company's agreement to issue new unregistered preferred investment options (the “New Options”) to purchase up to 1,617,190 shares of Common Stock
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Arcadia Biosciences, Inc. issued securities.
Exact text from the filing
On January 9, 2026, the Company agreed to reduce the exercise price for the Existing Options to $2.575 per share
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
Arcadia Biosciences, Inc. issued 56,602 shares of warrant to H.C. Wainwright & Co., LLC for placement agent services.
- Security
- warrant
- Shares
- 56,602 shares
- Purchaser
- H.C. Wainwright & Co., LLC
- Consideration
- placement agent services
Exact text from the filing
The Company also issued to Wainwright or its designees placement agent preferred investment options (the “Placement Agent Options”) to purchase that number of shares of Common Stock ("Placement Agent Option Shares") equal to 7.0% of the aggregate number of shares of Common Stock underlying the Existing Options exercised in the transaction, or 56,602 shares
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Arcadia Biosciences, Inc. entered into Inducement Letters with Participating Holders valued at Aggregate gross proceeds of approximately $2.1 million from exercise of Existing Options (effective 2026-01-09).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Participating Holders
- Value
- Aggregate gross proceeds of approximately $2.1 million from exercise of Existing Options
- Effective
- 2026-01-09
Exact text from the filing
On January 9, 2026, Arcadia Biosciences, Inc. (the “Company”) entered into inducement offer letter agreements (the “Inducement Letters”) with certain investors (the “Participating Holders”) pursuant to which such Participating Holders agreed to exercise certain outstanding preferred investment options to purchase an aggregate of 808,595 shares of the Company’s common stock ("Common Stock").
View on SEC.gov